Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Payables (2016 - 2025)

Altimmune (ALT) has disclosed Payables for 16 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Payables rose 1187.68% to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2025, up 1187.68% year-over-year, with the annual reading at $2.7 million for FY2025, 1187.68% up from the prior year.
  • Payables for Q4 2025 was $2.7 million at Altimmune, down from $4.8 million in the prior quarter.
  • The five-year high for Payables was $5.2 million in Q1 2023, with the low at $6083.0 in Q3 2021.
  • Average Payables over 5 years is $2.3 million, with a median of $2.1 million recorded in 2022.
  • The sharpest move saw Payables tumbled 99.3% in 2021, then skyrocketed 23227.31% in 2022.
  • Over 5 years, Payables stood at $2.0 million in 2021, then surged by 136.18% to $4.8 million in 2022, then tumbled by 56.91% to $2.1 million in 2023, then tumbled by 89.81% to $211000.0 in 2024, then soared by 1187.68% to $2.7 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $2.7 million, $4.8 million, and $851000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.